IMGO

Imago BioSciences, Inc. is a clinical-stage biopharmaceutical firm specializing in the identification and advancement of small molecule product candidates. These candidates are designed to inhibit lysine-specific demethylase 1 (LSD1), an enzyme integral to the generation of blood cells within the bone marrow. The company's flagship therapeutic, bomedemstat, is presently undergoing Phase II clinical trials. It is being developed as a potential treatment for myeloproliferative neoplasms, a class of chronic bone marrow malignancies that includes conditions such as myelofibrosis, essential thrombocythemia, and polycythemia vera. Established in 2012, Imago BioSciences is headquartered in South San Francisco, California.